Acute vascular rejection is associated with systemic complement activation in a pig-to-primate kidney xenograft model

Xenotransplantation

Volumn 7, Issue 3, 2000, Pages 186-196

  Loss, M ^a   Vangerow, B ^b   Schmidtko, J ^a   Kunz, R ^a   Jalali, A ^a   Arends, H ^a   Przemeck, M ^b   Ruckholt H ^b   Leuwer, M ^b   Kaup, F J ^c   Rensing, S ^c   Cozzi, E ^d   White, D J G ^d   Klempnauer, J ^a   Winkler, M ^a,b  

^a Klinik Für Viszeral und Transplantationschirurgie   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GERMAN PRIMATE CENTER   (Germany)

^d Imutran (A Novartis Pharma AG Company)   (United Kingdom)

Author keywords

Acute vascular rejection; Animal model; Complement; Xenotransplantation

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5B; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; PREDNISOLONE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; SWINE; TRANSGENIC ANIMAL; VASCULAR DISEASE; XENOGRAFT; XENOTRANSPLANTATION;

ACUTE DISEASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, HETEROPHILE; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOPHOSPHAMIDE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MACACA FASCICULARIS; SWINE; TIME FACTORS;

EID: 0033797721     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.2000.00059.x     Document Type: Article

References (23)

1. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement
2. The generation of transgenic pigs as potential organ donors for humans
3. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors
4. Organ transplantation between widely disparate species
5. Pig to monkey bone marrow and kidney xenotransplantation
6. Acute vascular rejection
7. Influence of cold ischemia time, pretransplant anti-porcine antibodies and donor/recipient size matching on hyperacute graft rejection following discordant porcine to cynomolgus kidney transplantation
8. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model
9. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts
10. Pig-to-primate cardiac xenotransplantation and cyclophosphamide therapy
11. Cyclophosphamide toxicity: Characterizing and avoiding the problem
12. Prolonged discordant xenograft survival and delayed xenograft rejection in a pig-to-baboon orthotopic cardiac xenograft model
13. Humoral responses to pig-to-baboon cardiac transplantation: Implications for the pathogenesis and treatment of acute vascular rejection and for accomodation
14. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants
15. Complement-fixing elicited antibodies are a major component in the pathogenesis of xenograft rejection
16. Suppression of delayed xenograft rejection by specific depletion of elicited antibodies of the IgM isotype
17. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients
18. Molecular barriers to xenotransplantation
19. Humoral responses to pig-to-baboon cardiac transplantation: Implications for the pathogenesis and treatment of acute vascular rejection and for accommodation
20. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor
21. Protection of porcine endothelial cells from complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection
22. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model